Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), have demonstrated promising survival benefits in patients with non-small cell lung cancer (NSCLC). Although the difference between TILs among the PD-L1-positive cases was comparatively small, PD-L1 positivity was less prevalent in EGFR-mutated tumors and more common in those with KRAS mutations, ROS1 translocations, BRAF mutations, or MET mutations.Д¬ancer immunotherapy has recently emerged as a new paradigm for treatment of lung cancer. Overall, KRAS, BRAF, PICK3A, MET mutations and ROS1 and RET translocations were more frequent, while EGFR and HER2 mutations and ALK translocations were less frequent compared with the overall PD-L1 expression levels. Conversely, PD-L1 expression was high in the presence of KRAS mutations (47.3% TPSвЂ‰в©ѕвЂ‰1% and 22.5% TPSвЂ‰в©ѕвЂ‰50%). PD-L1 expression in tumor cells was less frequent in patients harboring EGFR mutations (18.8% TPSвЂ‰в©ѕвЂ‰1% and 4.6% TPSвЂ‰в©ѕвЂ‰50%). PD-L1 expression was more common in patients who were mutation-negative irrespective of the TPS cutoff values and tumor size.

Contrastingly, TILs of 1154 (84.2%) and 346 (25.3%) patients stained positive at IPS cutoff values of в©ѕ1% and в©ѕ50%, respectively. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.In tumor cells, PD-L1 positivity was observed in 405 (29.6%), 122 (8.9%), and 27 (2.0%) patients with TPS cutoff values at в©ѕ1% and в©ѕ50%. Female patients with T1a adenocarcinoma in the right upper lobe barely had lymph node metastasis.Д¬hinese patients T1 non-small cell lung cancer lymph node metastases real-world risk factors. This real-world study showed the significant association of lymph node metastasis with age, tumor size, histology and differentiation, carcinoembryonic antigen levels, and status of vascular invasion. The univariate and multivariate analyses showed that younger age, squamous cell carcinoma, poor differentiation, larger tumor size, carcinoembryonic antigen level в‰Ґ5 ng/mL, and vascular invasion (+) were significantly associated with higher percentages of lymph node metastases (P < 0.001 for all). Of the patients, 3260 (29.9%) were current or former smokers. Most patients had T1b lung cancer (4766, 43.8%). A total of 1159 patients (10.6%) had metastases in mediastinal nodes (N2), and 640 patients (5.9%) had metastasis in pulmonary lymph nodes (N1). The median age was 60.0 years (range 12.9-86.6 years). The clinical and pathological factors associated with lymph node metastasis were analyzed by univariate and multivariate logistic regression.ДЄ total of 10 885 participants (51.6% women 15.3% squamous cell carcinoma) were included in the analysis. Clinical and pathological information was collected with the assistance of the Large-scale Data Analysis Center of Cancer Precision Medicine-LinkDoc database. This is a multicenter retrospective analysis of pathological T1 non-small cell lung cancer patients who underwent surgical resection from 2 January 2014 to 27 December 2017. However, the clinical characteristics of patients with lymph node metastasis in China are not fully understood.

13 Medical Affairs, Linkdoc Technology Co, Ltd, Beijing, China.ДЄpproximately 8.3-15.9% of patients with clinical stage I non-small cell lung cancer are subsequently shown to have lymph node metastasis.

12 Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China.

11 Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin, China.

10 Department of Thoracic Surgery, Henan Cancer Hospital, Zhengzhou, China.9 Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.8 Department of Thoracic Surgery, First Hospital Affiliated to Medical College of Zhejiang University, Hangzhou, China.7 Department of Thoracic Surgery, Chinese People's Liberation Army General Hospital, Beijing, China.

6 Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.5 Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.4 Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai, China.3 Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.2 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, China.1 Department of Thoracic Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.

Linkdoc technology ltd